Is Repare Therapeutics, Inc. overvalued or undervalued?

As of 1 March 2022, Repare Therapeutics, Inc. has moved from a valuation grade of "does not qualify" to "risky." The company is currently considered overvalued given its negative financial metrics, including a Price to Book Value of 0.50 and an EV to EBITDA ratio of 0.47. The Return on Equity (ROE) stands at a staggering -98.52%, indicating severe profitability issues.
In comparison to its peers, Tarsus Pharmaceuticals, Inc. has a P/E ratio of -16.08 and an EV to EBITDA of -12.26, while Travere Therapeutics, Inc. shows a P/E of -5.59 and an EV to EBITDA of -7.35. These figures suggest that Repare's valuation is not only high relative to its financial performance but also when compared to similarly positioned companies in the industry. Furthermore, the stock has underperformed significantly over the past year, declining by 60.06%, while the S&P 500 has gained 10.26%, reinforcing the notion that Repare Therapeutics is overvalued in the current market context.